禽流感疫苗市场规模份额、按疫苗类型、应用、菌株、给药途径、目标类型、分销渠道和地区分類的增长分析 - 行业预测，2025 年至 2032 年

2023 年全球禽流感疫苗市场规模价值为 1,458.8 亿美元，预计将从 2024 年的 1,520.1 亿美元成长到 2032 年的 2,112.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.2%。

禽流感主要由 H5N1 病毒株引起，其起源可追溯到水禽，并首次在中国发现，对中国家禽乃至人类健康构成重大风险。这种疾病有可能在全球蔓延，影响欧洲、亚洲和美洲的市场。禽流感疫苗包括H5、H7和H9疫苗，是控制疾病所必需的，中国是最大的生产国。同时，在美国，肝硬化影响了0.27％的成年人口，其中69％的人没有症状。主要风险因素包括糖尿病、酗酒和病毒性肝炎，与对照组相比，疾病的死亡率明显较高，凸显了紧迫的公共卫生需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 宏观经济指标
• 价值链分析
• 定价分析

禽流感疫苗市场规模（按疫苗类型和复合年增长率） (2025-2032)

• 市场概况
• 灭活疫苗
• 活重组疫苗
• 联合疫苗
• 重组疫苗
• 次单位疫苗

禽流感疫苗市场规模（依应用划分）及复合年增长率（2025-2032）

• 市场概况
• 鸡
• 鸭子和鹅
• 火鸡
• 其他的

禽流感疫苗市场规模（按菌株和复合年增长率） (2025-2032)

• 市场概况
• H5株
• H7株
• H9株

禽流感疫苗市场规模（按接种途径和复合年增长率） (2025-2032)

• 市场概况
• 肌肉注射
• 皮下
• 水性

禽流感疫苗市场规模：目标类型与复合年增长率（2025-2032）

• 市场概况
• 肉鸡
• 蛋鸡
• 育种者
• 后院家禽养殖

禽流感疫苗市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 兽医诊所
• 网路药局
• 零售商

禽流感疫苗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Sanofi（France）
• GlaxoSmithKline（GSK）（United Kingdom）
• Moderna Inc.（United States）
• Pfizer Inc.（United States）
• AstraZeneca（United Kingdom）
• Novavax, Inc.（United States）
• Vaxart, Inc.（United States）
• BioNTech SE（Germany）
• Sinovac Biotech Ltd.（China）
• Bharat Biotech International Ltd.（India）
• Serum Institute of India Pvt. Ltd.（India）
• Daiichi Sankyo Company, Limited（Japan）
• Mitsubishi Tanabe Pharma Corporation（Japan）
• Seqirus UK Limited（United Kingdom）
• Emergent BioSolutions Inc.（United States）
• Johnson & Johnson（United States）
• Abbott Laboratories（United States）
• Roche Holding AG（Switzerland）
• Merck & Co., Inc.（United States）

结论和建议

Global Avian Influenza Vaccine Market size was valued at USD 145.88 billion in 2023 and is poised to grow from USD 152.01 billion in 2024 to USD 211.25 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

Avian influenza, primarily driven by the H5N1 strain, poses significant risks to both domestic poultry and potential human health, with its origins traced back to waterfowl and an initial detection in China. The disease has the potential to spread globally, impacting markets across Europe, Asia, and the Americas. Vaccination strategies are crucial; the H5, H7, and H9 avian influenza vaccines are vital in disease control, with China emerging as the largest producer. Concurrently, in the U.S., cirrhosis affects 0.27% of the adult population, with a striking 69% unaware of their condition. Key risk factors include diabetes, alcohol abuse, and viral hepatitis, highlighting urgent public health needs as this condition carries a significantly higher mortality rate compared to matched control groups.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Avian Influenza Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Avian Influenza Vaccine Market Segmental Analysis

Global Avian Influenza Vaccine Market is segmented by Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Inactivated Vaccines, Live Recombinant Vaccines, Combination Vaccines, Recombinant Vaccines and Subunit Vaccines. Based on Application, the market is segmented into Chicken, Duck and Goose, Turkey and Others. Based on Strain, the market is segmented into H5 Strain, H7 Strain and H9 Strain. Based on Administration Route, the market is segmented into Intramuscular, Subcutaneous and Waterborne. Based on Target Species, the market is segmented into Broilers, Layers, Breeders and Backyard Poultry. Based on Distribution Channel, the market is segmented into Veterinary Clinics, Online Pharmacies and Retail Stores. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Avian Influenza Vaccine Market

The global avian influenza vaccine market is primarily driven by the escalating incidence of avian influenza, a disease caused by the avian influenza virus type A, predominantly found in waterfowl and transmissible to domestic chickens and various bird species. This virus can be categorized based on its surface proteins into subtypes of neuraminidase (NA) and hemagglutinin (HA), leading to classifications of highly pathogenic and low pathogenicity viruses. Despite nonpathogenic strains typically causing no visible symptoms, highly pathogenic variants pose a significant threat, resulting in severe disease outbreaks and high mortality rates in poultry, thereby underscoring the urgent need for effective vaccination.

Restraints in the Global Avian Influenza Vaccine Market

The Global Avian Influenza Vaccine market faces significant restraints due to the challenges posed by the rapid mutation of the avian influenza virus. This high mutation rate complicates efforts to ensure effective vaccine coverage, as the vaccines may become less effective against emerging strains. Consequently, ongoing research is crucial to comprehend the virus's dynamics and to enhance vaccine formulation and efficacy. As researchers strive to adapt to these viral changes, the demand for innovative solutions in vaccine development becomes increasingly essential, highlighting the need for continuous investment in avian influenza research to bolster public health responses to this ongoing threat.

Market Trends of the Global Avian Influenza Vaccine Market

The Global Avian Influenza Vaccine market is witnessing significant growth, particularly in the Asia-Pacific region, driven by countries like Israel, China, India, and South Korea, which report high incidences of bird flu viruses. The region's increasing focus on enhancing supply chain efficiencies and bolstering research and development through favorable government policies is expected to accelerate vaccine production and distribution. Furthermore, rising awareness around biosecurity measures in poultry farming and the necessity for preventive health strategies further stimulate market demand. This combination of factors is poised to shape a robust market trend, promoting innovation in avian influenza vaccines on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Avian Influenza Vaccine Market Size by Vaccine Type & CAGR (2025-2032)

• Market Overview
• Inactivated Vaccines
• Live Recombinant Vaccines
• Combination Vaccines
• Recombinant Vaccines
• Subunit Vaccines

Global Avian Influenza Vaccine Market Size by Application & CAGR (2025-2032)

• Market Overview
• Chicken
• Duck and Goose
• Turkey
• Others

Global Avian Influenza Vaccine Market Size by Strain & CAGR (2025-2032)

• Market Overview
• H5 Strain
• H7 Strain
• H9 Strain

Global Avian Influenza Vaccine Market Size by Administration Route & CAGR (2025-2032)

• Market Overview
• Intramuscular
• Subcutaneous
• Waterborne

Global Avian Influenza Vaccine Market Size by Target Species & CAGR (2025-2032)

• Market Overview
• Broilers
• Layers
• Breeders
• Backyard Poultry

Global Avian Influenza Vaccine Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Veterinary Clinics
• Online Pharmacies
• Retail Stores

Global Avian Influenza Vaccine Market Size & CAGR (2025-2032)

• North America (Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel)
  • US
  • Canada
• Europe (Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxart, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinovac Biotech Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seqirus UK Limited (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations